Epigenetics of melanoma;Epigenetyka czerniaka

Wspolczesna Onkologia

Volumn 12, Issue 2, 2008, Pages 45-50

  Kwinta, Łukasz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CpG islands; DNA methylation; Epigenetics; Histones; Melanoma; Post translational modifications

Indexed keywords

CYTOSINE; DNA; DNA BINDING PROTEIN; HISTONE;

ACETYLATION; ARTICLE; CHROMATIN STRUCTURE; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; HUMAN; MELANOMA; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SKIN CARCINOGENESIS; SUMOYLATION; UBIQUITINATION;

EID: 44649158235     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bird A. DNA methylation patterns andepigenetic memory. Genes Dev 2002; 16: 6-21.
2. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol 2003; 15: 172-83.
3. Górska I, Kempisty B, Jagodziński PP. Epigenetyczne modyfikacje w komórkach rozrodczych. Ginekol Prakt 2006; 3: 2-5.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
5. Russo VE, Martienssen RA, Riggs AD. Epigenetic Mechanisms of Gene Regulation. Cold Spring Harbor Laboratory Press, New York 1996.
6. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997; 88: 471-81.
7. Bird A. DNA methylation patterns andepigenetic memory. Genes Dev 2002; 16: 6-21.
8. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 1992; 20: 5085-92.
9. Lewis JD, Meehan RR, Henzel WJ, Mauer-Fogy I, Jeppesen P, Klein F, Bird A. Purification, sequence and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992; 69: 905-14.
10. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time dependent repression of transcription initiation. Curr Biol 1997; 7: 157-65.
11. Nan X, Tate P, Li E, Bird A. DNA Methylation Specifies Chromosomal Localization of MeCP2. Mol Cell Biol 1996; 16: 414-21.
12. McArthur M, Thomas JO. A preference of histone H1 for methylated DNA. EMBO J 1996; 15: 1705-14.
13. van der Velden PA, Zuidervaart W, Hurks MH et al. Expression profiling reveals that methylation of TIMP3 is involvedin uveal melanoma development. Int J Cancer 2003; 106: 472-9.
14. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager M J. Promoter hipermethylation: a common cause of reduced p16 (INK4a) expression in uveal melanoma. Cancer Res 2001; 61: 5303-6.
15. Soengas MS, Capodieci, P. Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-11
16. Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, Yamamoto Y, Sugihara T, Moriuchi T. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int Oncol 2004; 25: 1415-21
17. Radosevich M, Jager M, Ono SJ. Inhibition o MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Experimental and Molecular Pathology 2007; 82: 68-76.
18. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hipermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002; 161: 229-37.
19. Gmyrek G, Kwiatkowska E, Lamperska K, Mackiewicz A. Analiza metylacji wysp CpG w odcinkach promotorowych genów p16 i p15 w czerniaku złośliwym skóry i gałki ocznej. Współcz Onkol 2001; 5: 10-2.
20. Merbs LS, Sindransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primery sporadic uveal melanoma. IOVS 1999; 40: 779-83.
21. Okano M, Bell DW, Haber DA, Li E. DNA methylotransferases Dnmt3a and Dmnt3b are essential for de novo methylation and mammalian development. Cell 1999; 99: 247-57.
22. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann. Oncol 2002; 13: 1699-716.
23. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66: 6080-6.
24. Feinberg AP, Vogelstein B. Hipomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
25. Smith SS, Crocitto L. DNA methylation in eukaryotic chromosome stability revisited: DNA methyltransferase in the management of DNA conformation space. Mol Carcinog 1999; 26: 1-9.
26. Qu GZ, Grundy PE, Narayan A, Ehrlich M. Frequent hipomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 1999; 109: 34-9.
27. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MACE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996; 93: 7149-53.
28. Sigalotti L, Coral S, Nardi C, et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 2002; 25: 16-26.
29. Fontijn D, Adema AD, Bhakat KK, Pinedo HM, Peters GJ, Boven E. O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor - induced resistance against temozolomide in human melanoma cells. Mol Cancer Ther 2007; 6: 2807-15.
30. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005; 41: 2381-402.
31. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2000; 15: 2343-60.
32. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-12.
33. Thrower JS, Hoffman L, Rechsteiner M, Pickard CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 94-102.
34. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002; 513: 124-8.
35. Dong Z, Bode AM. The role of histone H3 phosphorylation (Ser10 and Ser 28) in cell growth and cell transformation. Mol Carcinog 2006; 45: 416-21.
36. Bergink S, Salomons FA, Hoogstraten D, et al. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev 2006; 20: 1343-1352.
37. Warters RL, Adamson PJ, Pond CD, Leachman SA. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol 2005; 124: 807-17.
38. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000; 5: 905-15.
39. Winter S, Simboeck E, Fischle W, Zupkovitz C, Dohnal I, Mechtler K, Ammerer G, Seiser C. 14-3-3 proteins recognize a histone code at histone H3 and are required for transcriptional activation. EMBO J 2008; 27: 88-99.
40. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, Zhang Y. Purification an dfunctional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell 2001; 8: 1207-17.
41. Sun ZW, Allis CD. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 2002; 418: 104-8.
42. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of Histone Deacetylase 1 Confers Resistance to Sodium Butyrate-Mediated Apoptosis in Melanoma Cells through a p53-Mediated Pathway. Cancer Res 2004; 64: 7706-10.
43. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004; 9: 573-82.
44. Peltonen K, Kiviharju TM, Jarvinen PM, Ra R, Laiho M. melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res 2005; 18: 196-202.
45. Kobayashi Y, Ohtsuki M, Murakami T, et al. Histone deacetylase inhibitor FK228 supresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 2006; 25: 512-24.
46. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005; 11: 4912-22.
47. Hellebrekers DMEI, Castermans K, Vire E, et al. Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. Cancer Res 2006; 66: 10770-7.
48. Huang C, Sloan EA, Boerkoel CF. Chromatin remodeling and human disease. Curr Opin Genet Dev 2003; 13: 246-52.
49. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007; 26: 77-90.